In a research note issued to investors, Brian Klein at Stifel Nicolaus Reiterated their Buy rating on Clovis Oncology Inc (NASDAQ:CLVS). The analyst placed a $125.00 price target on the stock which indicates a 37.09% upside to the last closing price. In the year following Brian’s ratings, the stocks covered yield an average return of -5.2% according to TipRanks.com. In the past year 11 out of 21 recommendations or 52% were successful.
Wall Street analysts have placed a target price of $104.25 for Clovis Oncology, Inc. (NASDAQ:CLVS). This number is based on the mean consensus estimate from the 4 research firms that recently issued reports on the stock.
The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 1.5 based on 4 broker recommendations. Of the 4 analysts who have issued estimates, the most bullish sees the stock reaching $125 within the next 12 months while the most conservative sees the stock at $92 within the year.
According to analysts, Clovis Oncology, Inc. (NASDAQ:CLVS) is expected to report earnings per share for the current fiscal quarter of $-2.16. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-1.86. The reported number was -0.08 away from the consensus estimate, or a surprise factor of -4.49 .
In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.